As of Nov 19, 2026, 2 of 2 active firms rate MGX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MGX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.47
Range $-0.55 – $-0.39 · 2 analysts · -23% YoY
Next period, 2 analysts expect Metagenomi, Inc. Common Stock to earn $-0.47 a share (range $-0.55 – $-0.39), versus $-0.61 a year earlier. Full-year consensus is $-2.42, growing to $-1.83 the year after.
REVENUE · NEXT QUARTER
$2.6M
Range $2.5M – $2.8M · 2 analysts · +112% YoY
Revenue is expected to reach $2.6M (range $2.5M – $2.8M), +112.3% year-over-year. Full-year consensus is $5.4M, rising to $7.5M next year.
Top analysts covering Metagenomi, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MGX.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$5.00+693.7% to target
Overall win rate
41%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$7.00+1011.1% to target
Overall win rate
33%
+ Follow
#3
Yanan Zhu
Wells Fargo
Buy
$7.00+1011.1% to target
Coverage
—
+ Follow
#4
Joseph Thome
TD Cowen
Buy
No targeton MGX
Coverage
—
+ Follow
MGX stock forecast FAQ
What is MGX's average 12-month price target?+
The 2 active firms with a live target average $6.00 for Metagenomi, Inc. Common Stock over the next 12 months, ranging from a $7.00 high to a $5.00 low, as of Nov 19, 2026.
Is MGX stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MGX?+
The Street-high target is $7.00 (Wells Fargo), and the Street-low is $5.00 (Chardan Capital). The average of all 2 active-firm targets is $6.00.
How many active Wall Street firms cover MGX?+
2 active firms have a recognized rating on Metagenomi, Inc. Common Stock as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MGX?+
Among analysts who currently cover MGX, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $5.00 target.
What is Metagenomi, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.47 per share (range $-0.55 – $-0.39) across 2 analysts. Full-year EPS is projected at $-2.42, rising to $-1.83 the following year.
How much revenue is Metagenomi, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $2.6M (range $2.5M – $2.8M). Full-year revenue is projected at $5.4M, growing to $7.5M next year.
Have analysts been upgrading or downgrading MGX lately?+
As of Nov 19, 2026, 2 of 2 active firms rate MGX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MGX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.